Clinical Pearls on Treating Patients with NRG1 Fusions
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, offer key takeaways and conclude their discussion by offering advice for clinicians treating patients with NRG1 fusion–positive malignancies.
Practical Considerations for Zenocutuzumab in NRG1 Fusion–Positive Malignancies
Drs Macarulla and Neuzillet discuss the role of zenocutuzumab in the treatment of patients with NRG1 fusion–positive solid tumors.
Recent Data on Zenocutuzumab at ESMO 2023
Experts on pancreatic cancer review recent data on zenocutuzumab in patients with NRG1 fusion–positive GI malignancies.
NRG1 Fusion Testing Practices
Medical oncologists provide insights on the evolving molecular testing practices for NRG1 fusions.
Overview of NRG1 Fusions
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, define NRG1 fusions and outline their incidence and effect on prognosis.